Investigation of KIR/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML)
Background KIR/HLA mismatch in hematopoietic stem cell transplantation (HSCT), particularly in patients with acute myeloid leukemia (AML), was related to decreased recurrence rates, improved engraftment, and a reduction in graft-versus-host disease, according to recent research (GVHD). Uncertainty exists about the impact of KIR/HLA mismatch on haploidentical-HSCTs treated with post-transplant cyclophosphamide (PTCy). We attempted to analyze the effects of KIR/HLA mismatch on clinical outcomes on transplant outcomes using the cohort of 54 AML patients who received a haplo-HSCT with PTCy. Results In contrast to KIR/HLA match, our findings showed that donor KIR/HLA mismatch was substantially associated with superior OS (HR, 2.92; (P = 0.04)). Moreover, donor KIR/HLA mismatch ($ KIR2DS1_{D} $/$ C2^{+} $R and $ KIR2DS2_{D} $/$ C1^{+} $R mismatch versus $ KIR2DL1_{D} $/$ C2^{−} $R mm, KIR2DL2/$ 3_{D} $/$ C1^{−} $R mm and $ KIR3DL1_{D} $/$ Bw4^{−} $ mm) was correlated with the improvements in OS (HR, 0.74; P = 0.085) and activating. KIR/HLA mismatch versus KIR/HLA match was significantly correlated with improvements in OS (HR, .46; P = 0.03) and inhibitory. KIR/HLA mismatch versus KIR/HLA match was enhancement in the OS (HR, .93; P = 0.06). Despite a higher rate of aGvHD (grade I-IV) in the patients with KIR/HLA mismatch compared to KIR/HLA matched (57% vs. 33% (p = 0.04). However, the KIR/HLA mismatch group saw a decreased relapse rate (3.2% vs. 23%, p = 0.04). Conclusion This analysis shows the significance of KIR/HLA Incompatibility, other clinical variables like CMV, the relationship between donor/recipient and donor age, and the relationship between donor/recipient and donor age in the haplo-donor selection process. It also suggests that KIR and HLA mismatching between donor and recipient could be routinely performed for haplo-donor selection and may improve clinical outcomes after haplo-HSCTs with PTCy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
BMC immunology - 24(2023), 1 vom: 20. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bakhtiari, Tahereh [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Acute myeloid leukemia |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s12865-023-00548-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR051965577 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR051965577 | ||
| 003 | DE-627 | ||
| 005 | 20230621064805.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230621s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12865-023-00548-1 |2 doi | |
| 035 | |a (DE-627)SPR051965577 | ||
| 035 | |a (SPR)s12865-023-00548-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bakhtiari, Tahereh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Investigation of KIR/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background KIR/HLA mismatch in hematopoietic stem cell transplantation (HSCT), particularly in patients with acute myeloid leukemia (AML), was related to decreased recurrence rates, improved engraftment, and a reduction in graft-versus-host disease, according to recent research (GVHD). Uncertainty exists about the impact of KIR/HLA mismatch on haploidentical-HSCTs treated with post-transplant cyclophosphamide (PTCy). We attempted to analyze the effects of KIR/HLA mismatch on clinical outcomes on transplant outcomes using the cohort of 54 AML patients who received a haplo-HSCT with PTCy. Results In contrast to KIR/HLA match, our findings showed that donor KIR/HLA mismatch was substantially associated with superior OS (HR, 2.92; (P = 0.04)). Moreover, donor KIR/HLA mismatch ($ KIR2DS1_{D} $/$ C2^{+} $R and $ KIR2DS2_{D} $/$ C1^{+} $R mismatch versus $ KIR2DL1_{D} $/$ C2^{−} $R mm, KIR2DL2/$ 3_{D} $/$ C1^{−} $R mm and $ KIR3DL1_{D} $/$ Bw4^{−} $ mm) was correlated with the improvements in OS (HR, 0.74; P = 0.085) and activating. KIR/HLA mismatch versus KIR/HLA match was significantly correlated with improvements in OS (HR, .46; P = 0.03) and inhibitory. KIR/HLA mismatch versus KIR/HLA match was enhancement in the OS (HR, .93; P = 0.06). Despite a higher rate of aGvHD (grade I-IV) in the patients with KIR/HLA mismatch compared to KIR/HLA matched (57% vs. 33% (p = 0.04). However, the KIR/HLA mismatch group saw a decreased relapse rate (3.2% vs. 23%, p = 0.04). Conclusion This analysis shows the significance of KIR/HLA Incompatibility, other clinical variables like CMV, the relationship between donor/recipient and donor age, and the relationship between donor/recipient and donor age in the haplo-donor selection process. It also suggests that KIR and HLA mismatching between donor and recipient could be routinely performed for haplo-donor selection and may improve clinical outcomes after haplo-HSCTs with PTCy. | ||
| 650 | 4 | |a KIR/HLA mismatch |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a KIR/HLA match |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Acute myeloid leukemia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Post-transplant cyclophosphamide |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Haploidentical Transplant |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a HSCT |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Ahmadvand, Mohammad |4 aut | |
| 700 | 1 | |a Yaghmaie, Marjan |4 aut | |
| 700 | 1 | |a Sadeghi, Alireza |4 aut | |
| 700 | 1 | |a Mousavi, Seied Asadollah |4 aut | |
| 700 | 1 | |a Rostami, Tahereh |4 aut | |
| 700 | 1 | |a Ganjalikhani-Hakemi, Mazdak |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC immunology |d London : BioMed Central, 2000 |g 24(2023), 1 vom: 20. Juni |w (DE-627)SPR027163288 |w (DE-600)2041500-X |x 1471-2172 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:1 |g day:20 |g month:06 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12865-023-00548-1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 1 |b 20 |c 06 | ||